Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Core Viewpoint - Praxis Precision Medicines, Inc. has announced a public offering of 2,212,000 shares of common stock priced at $260.00 per share, aiming to raise approximately $575 million in gross proceeds before expenses [1]. Group 1: Offering Details - The offering consists of 2,212,000 shares at a price of $260.00 per share, with expected gross proceeds of around $575 million [1]. - Praxis has granted underwriters a 30-day option to purchase up to 331,800 additional shares at the same public offering price [1]. - The offering is anticipated to close on or about January 8, 2026, subject to market conditions and customary closing conditions [1]. Group 2: Underwriters - Piper Sandler, TD Cowen, Guggenheim Securities, and Truist Securities are acting as joint book-running managers for the offering [2]. - LifeSci Capital, Baird, and Oppenheimer & Co. are serving as lead managers, while H.C. Wainwright & Co. and Needham & Company are co-managers [2]. Group 3: Regulatory Information - The offering is made under a shelf registration statement on Form S-3ASR, which became effective upon filing with the SEC on December 23, 2024 [3]. - A preliminary prospectus supplement was filed with the SEC on January 6, 2026, and the final prospectus will also be filed with the SEC [3].